- Home
- LNZA vs ESPR Comparison
LNZA vs ESPR Comparison
Compare LNZA & ESPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LNZA
- ESPR
- Stock Information
- Founded
- LNZA 2005
- ESPR 2008
- Country
- LNZA United States
- ESPR United States
- Employees
- LNZA N/A
- ESPR N/A
- Industry
- LNZA Major Chemicals
- ESPR Biotechnology: Pharmaceutical Preparations
- Sector
- LNZA Industrials
- ESPR Health Care
- Exchange
- LNZA Nasdaq
- ESPR Nasdaq
- Market Cap
- LNZA 340.2M
- ESPR 399.0M
- IPO Year
- LNZA N/A
- ESPR 2013
- Fundamental
- Price
- LNZA $1.02
- ESPR $2.19
- Analyst Decision
- LNZA Strong Buy
- ESPR Buy
- Analyst Count
- LNZA 4
- ESPR 5
- Target Price
- LNZA $5.75
- ESPR $7.30
- AVG Volume (30 Days)
- LNZA 607.3K
- ESPR 8.9M
- Earning Date
- LNZA 11-08-2024
- ESPR 11-07-2024
- Dividend Yield
- LNZA N/A
- ESPR N/A
- EPS Growth
- LNZA N/A
- ESPR N/A
- EPS
- LNZA N/A
- ESPR N/A
- Revenue
- LNZA $58,025,000.00
- ESPR $295,451,000.00
- Revenue This Year
- LNZA N/A
- ESPR $186.90
- Revenue Next Year
- LNZA $102.41
- ESPR $31.10
- P/E Ratio
- LNZA N/A
- ESPR N/A
- Revenue Growth
- LNZA 7.99
- ESPR 187.12
- 52 Week Low
- LNZA $0.84
- ESPR $1.58
- 52 Week High
- LNZA $5.73
- ESPR $3.94
- Technical
- Relative Strength Index (RSI)
- LNZA 43.72
- ESPR 42.08
- Support Level
- LNZA $0.84
- ESPR $2.12
- Resistance Level
- LNZA $1.04
- ESPR $2.54
- Average True Range (ATR)
- LNZA 0.09
- ESPR 0.39
- MACD
- LNZA 0.02
- ESPR -0.13
- Stochastic Oscillator
- LNZA 51.43
- ESPR 16.67
About LNZA LanzaTech Global Inc.
LanzaTech Global Inc is a nature-based carbon refining company that transforms waste carbon into the chemical building blocks for consumer goods such as sustainable fuels, fabrics, and packaging that people use in their daily lives. The company's goal is to reduce the need for virgin fossil fuels by challenging and striving to change the way the world uses carbon.
About ESPR Esperion Therapeutics Inc.
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The Company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.